Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes
Viruses · 26.10.2025 · 17 (11) · 1422
DOI: 10.3390/v17111422 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 26.10.2025. Verfasst von Hoor AlKaabi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Internal Medicine, The Medical City for Military and Security Services, Muscat 111, Oman. Hauptthemen laut MEDLINE: Antiviral Agents, Hepacivirus, Immunocompromised Host, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) management, offering high cure rates, favorable safety, and simplified regimens. Management in immunosuppressed patients remains challenging due to drug–drug interactions (DDIs). The objective of this review is to summarize clinical outcomes, safety, and pharmacologic considerations of DAA therapy in immunosuppressed patients, including solid organ transplant recipients and those on biological agents. We reviewed clinical studies, pharmacologic databases, and guidelines to characterize DAA classes, mechanisms, and relevant DDIs in immunosuppressed HCV patients. In transplant recipients, DAAs achieved sustained virological response (SVR) > 90% with minimal graft rejection. Safety profiles were favorable, and immunosuppressant dose adjustments were rarely needed. DDIs, particularly with calcineurin inhibitors (tacrolimus, cyclosporine), require careful monitoring due to variable trough-level effects. Evidence also supports the efficacy and safety of DAAs in patients on biological agents, without compromising SVR. Pharmacokinetic data indicate DAAs maintain antiviral activity across HCV genotypes in the presence of immunosuppressants, though mTOR inhibitors may alter efficacy in certain HCV genotypes. DAAs are highly effective and safe in immunosuppressed patients, achieving high SVR rates and potential graft survival benefits. Prospective studies are needed to assess DAA therapy in patients receiving biological agents and to optimize co-administration strategies with immunosuppressive agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Internal Medicine, The Medical City for Military and Security Services, Muscat 111, Oman.
- Department of Child Health, Sultan Qaboos University Hospital, University Medical City, Muscat 123, Oman.
- Department of Child Health, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat 123, Oman.
- Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo11795, Egypt.
- Applied Science Research Center, Applied Science Private University, Amman 11931, Jordan.
- Steatotic Liver Diseases Study Foundation in the Middle East and North Africa (SLMENA), Cairo 11795, Egypt.
ORCID-Profile: Mohamed El-Kassas, Khalid M AlNaamani
Zitieren
APA
AlKaabi, H., AlSinani, S., El-Kassas, M., Alswat, K. A., & AlNaamani, K. M. (2025). Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes. Viruses, 17(11), 1422. https://doi.org/10.3390/v17111422
Vancouver
AlKaabi H, AlSinani S, El-Kassas M, Alswat KA, AlNaamani KM. Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes. Viruses. 2025;17(11):1422. doi:10.3390/v17111422
BibTeX
@article{AlKaabi2025,
author = {AlKaabi, Hoor and AlSinani, Siham and El-Kassas, Mohamed and Alswat, Khalid A and AlNaamani, Khalid M},
title = {Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes},
journal = {Viruses},
year = {2025},
volume = {17},
number = {11},
pages = {1422},
doi = {10.3390/v17111422}
}
EUVIMED